Hetero gets DCGI nod to launch COVID-19 drug

By: |
Updated: Jun 21, 2020 3:36 PM

The company has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of COVID-19, it said in a statement.

Hetero, DCGI, COVID-19 drug, remdesivir, COVID-19 treatment, latest news on coronavirus drugThe product is being launched under a licensing agreement with Gilead Sciences Inc to expand access to COVID-19 treatment in low and middle-income countries, it added. (Representational image: Reuters)

Drug firm Hetero on Sunday said it has received approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the treatment of COVID-19 after getting. The company has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of COVID-19, it said in a statement.

The company’s generic version of Remdesivir will be marketed under the brand name ‘Covifor’ in India. The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, it added.

“In the light of increasing COVID-19 cases in India, the approval of ‘Covifor’ (remdesivir) can prove to be a game-changer given its positive clinical outcomes. “Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,”Hetero Group of Companies Chairman B Partha Saradhi Reddy said.

The company is prepared for ensuring enough stock to cater to the present needs, he added. The drug will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner,Hetero said.

The product is being launched under a licensing agreement with Gilead Sciences Inc to expand access to COVID-19 treatment in low and middle-income countries, it added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Govt depressing Covid-19 testing, says Thyrocare CEO
2Dr Reddy’s hopes to finish Phase 3 trials of Covid-19 vaccine by March-May
3Union Minister Smriti Irani tests positive for Covid-19 infection amid intense Bihar poll campaign